KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Receivables data on record, last reported at $27.5 million in Q4 2025.

  • For Q4 2025, Receivables rose 247.3% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, up 247.3%, while the annual FY2025 figure was $27.5 million, 247.3% up from the prior year.
  • Receivables reached $27.5 million in Q4 2025 per AQST's latest filing, up from $14.1 million in the prior quarter.
  • Across five years, Receivables topped out at $27.5 million in Q4 2025 and bottomed at $4.9 million in Q2 2024.
  • Average Receivables over 5 years is $12.9 million, with a median of $11.2 million recorded in 2023.
  • Peak YoY movement for Receivables: plummeted 62.24% in 2022, then soared 247.3% in 2025.
  • A 5-year view of Receivables shows it stood at $18.1 million in 2021, then tumbled by 62.24% to $6.8 million in 2022, then surged by 66.39% to $11.4 million in 2023, then plummeted by 30.42% to $7.9 million in 2024, then skyrocketed by 247.3% to $27.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $27.5 million in Q4 2025, $14.1 million in Q3 2025, and $10.3 million in Q2 2025.